Table 3.

Overall diagnostic performance of each subset and the stratified or meta-regression analysis result for version 1.0

Parameter	Sensitivity	Specificity	Meta-regression analysis (p value)
Lung-RADS version			0.03
Version 1.0 subset (n = 27)	0.96 [0.90–0.99]	0.90 [0.87–0.92]
Version 1.1 subset (n = 4)	0.91 [0.83–0.96]	0.81 [0.67–0.90]
Version 1.0 subset
Population type			< 0.001
High-risk population (n = 21)	0.98 [0.92–0.99]	0.87 [0.85–0.89]
General population (n = 6)	0.84 [0.50–0.96]	0.95 [0.92–0.97]
Population area			0.02
Non-Asia (n = 19)	0.97 [0.91–0.99]	0.88 [0.85–0.90]
Asia (n = 8)	0.91 [0.67–0.98]	0.93 [0.88–0.96]
Study design			0.45
Prospective (n = 14)	0.97 [0.88–0.99]	0.88 [0.84–0.91]
Retrospective (n = 13)	0.96 [0.82–0.99]	0.91 [0.87–0.94]
Reference standard			0.22
Pathology alone (n = 21)	0.94 [0.84–0.98]	0.90 [0.86–0.92]
Pathology and other methods (n = 6)	0.99 [0.88–1.00]	0.89 [0.88–0.90]
Prevalence of lung cancer			0.02
< 1.9% (n = 13)	0.93 [0.83–0.98]	0.92 [0.88–0.94]
≥ 1.9% (n = 14)	0.96 [0.86–0.99]	0.87 [0.84–0.89]

The median lung cancer prevalence was 1.9% among the included studies